Latest News and Press Releases

LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension studyInitiated...

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board...

ATHENS, Greece, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes,...

Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as...

Q4’22 Financial Results and Recent Business Highlights Revenue of $476.4 millionIoT revenue increased 87% YoYRecord GAAP gross margin of 55.9 percentNon-GAAP gross margin of 61.0 percentGAAP...

TROY, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) --  Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) that provides software and cloud solutions in...

On track to report data from all three clinical programsSecond quarter ending cash of $185.5 million expected to fund operations into the first quarter of 2024 BELTSVILLE, Md., Aug. 04, 2022 (GLOBE...

Company continuing to enroll patients in both Phase 3 registrational AGILITY trial of entospletinib and Phase 1/2 KB-0742 trial; both programs remain on track Preclinical data at EHA further support...

--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with...

TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...